British journal of haematology 2012-05
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Related Questions
For example, if the patient was on dasatinib before relapse, would you consider other second generation or third generation TKIs?
New answer by at CHU Sainte-Justine (September 5, 2020)
Mechanisms of resistance in Ph-like ALL have not been extensively studied and will definitively be an active area of research. Given the biological similarities between Ph+ AL...